Tixagevimab/cilgavimab

Summary

To ask the Secretary of State for Health and Social Care, what assessment he has made of the effectiveness of the AstraZeneca drug Evusheld for immunosuppressed people in the UK; what plans he has to use that drug as a (a) prophylactic and (b) treatment;

This text is taken from the official record. PoliticalRepo does not editorialize.

Timeline

1. 13 December 2021

   Written question

   To ask the Secretary of State for Health and Social Care, what assessment he has made of the effectiveness of the AstraZeneca drug Evusheld for immunosuppressed people in the UK; what plans he has to use that drug as a (a) prophylactic and (b) treatment;

   Source: Commons

2. 20 December 2021

   Answer

   We continue to monitor the emerging data for AstraZeneca’s long-acting antibody therapy, AZD7442, also known as Evusheld. AstraZeneca have discussed potential approvals with the Medicines and Healthcare products Regulatory Agency .The Department published...

   Source: Written answer

Votes

No vote records are attached yet.

Versions

No version snapshots stored. Document URLs remain at the source.

Documents

No documents linked.

Sponsors

• · Department of Health and Social Care · Answering body

Related records

No cross-record relationships stored yet.